Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for NMO patients: antibody therapies under Real-World scrutiny

NCT ID NCT06885957

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 23 times

Summary

This study tracks 200 adults with a specific type of neuromyelitis optica (NMO), a rare disease that attacks the optic nerves and spinal cord. Researchers are monitoring how well different antibody-based medicines work in everyday medical practice, focusing on preventing relapses and checking safety. Participants will be followed over time to see how the disease changes in the brain and immune system.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NMO SPECTRUM DISORDER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430030, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.